GlaxoSmithKline Pharmaceuticals Profit & Loss Annual
BSE: - | NSE: - | ISIN: - | Sector: -| Fiscal Period | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Period End Date | Mar 26 | Mar 25 | Mar 24 | Mar 23 |
| Total Operating Expense | 2,578.91 | 2,634.86 | 2,778.00 | 2,513.91 |
| Other Net | 145.36 | 4.77 | 4.85 | -0.37 |
| Diluted Weighted Average Shares | 17.23 | 16.94 | 16.94 | 16.94 |
| Gain( Loss)on Saleof Assets | 20.62 | 3.18 | 20.58 | 9.67 |
| Depreciation/ Amortization | 66.44 | 66.66 | 69.54 | 65.62 |
| Operating Income | 1,242.76 | 1,114.35 | 675.71 | 737.81 |
| Net Income | 1,035.98 | 927.58 | 589.96 | 610.69 |
| Income Availableto Com Excl Extra Ord | 1,035.98 | 927.58 | 589.96 | 607.64 |
| Other Operating Expenses Total | 554.16 | 60.64 | 61.01 | 52.24 |
| Net Income Before Taxes | 1,406.01 | 1,259.88 | 816.19 | 836.40 |
| Net Income After Taxes | 1,035.98 | 927.58 | 589.96 | 607.64 |
| Income Availableto Com Incl Extra Ord | 1,035.98 | 927.58 | 589.96 | 610.69 |
| Costof Revenue Total | 1,351.06 | 1,512.30 | 1,457.10 | 1,394.28 |
| Gross Profit | 2,470.61 | 2,236.91 | 1,996.61 | 1,857.44 |
| Interest Inc( Exp) Net- Non- Op Total | -2.73 | 137.58 | 115.05 | 89.29 |
| Diluted Net Income | 1,035.98 | 927.58 | 589.96 | 610.69 |
| DPS- Common Stock Primary Issue | 57.00 | 42.00 | 32.00 | 32.00 |
| Provisionfor Income Taxes | 370.03 | 332.30 | 226.23 | 228.76 |
| period Type | - | - | - | - |
| Net Income Before Extra Items | 1,035.98 | 927.58 | 589.96 | 607.64 |
| Total Revenue | 3,821.67 | 3,749.21 | 3,453.71 | 3,251.72 |
| period Length | 12.00 | 12.00 | 12.00 | 12.00 |
| Revenue | 3,821.67 | 3,749.21 | 3,453.71 | 3,251.72 |
| Selling/ General/ Admin Expenses Total | 607.25 | 995.12 | 1,026.91 | 991.00 |
| Diluted Normalized EPS | 59.23 | 54.62 | 40.92 | 35.91 |
| Diluted EPS Excluding Extra Ord Items | 60.11 | 54.76 | 34.83 | 35.87 |
| Interest Exp( Inc) Net- Operating Total | - | 0.13 | 0.14 | 0.14 |
| Total Extraordinary Items | - | - | 0.00 | 3.04 |
| Unusual Expense( Income) | - | - | 163.30 | 10.61 |
GlaxoSmithKline Pharmaceuticals Quick Links
GlaxoSmithKline Pharmaceuticals Dividend GlaxoSmithKline Pharmaceuticals Bonus GlaxoSmithKline Pharmaceuticals News GlaxoSmithKline Pharmaceuticals AGM GlaxoSmithKline Pharmaceuticals Rights GlaxoSmithKline Pharmaceuticals Splits GlaxoSmithKline Pharmaceuticals Board Meetings GlaxoSmithKline Pharmaceuticals Key Metrics GlaxoSmithKline Pharmaceuticals Shareholdings GlaxoSmithKline Pharmaceuticals Balance Sheet GlaxoSmithKline Pharmaceuticals Cashflow GlaxoSmithKline Pharmaceuticals Q1 Results GlaxoSmithKline Pharmaceuticals Q2 Results GlaxoSmithKline Pharmaceuticals Q3 Results GlaxoSmithKline Pharmaceuticals Q4 Results
Equity Quick Links
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.